AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11248608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily and Tolterodine IR 2 mg twice daily
Number of subjects: 1529
Study 9227717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast, 450 mg twice daily
Number of subjects: 8
Study 9227717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8039526 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antidiabetic drugs
Number of subjects: 454
Study 8039526 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 454
Study 8039526 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic drugs
Number of subjects: 454
Study 8039526 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral drugs
Number of subjects: 454
Study 8039526 — intervention group
Group type: EXPERIMENTAL
Intervention: Active approach to pharmacological treatment
Number of subjects: 454
Study 8039526 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic control
Number of subjects: 454
Study 3583495 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 40
Study 3583495 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 40
Study 29567435 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezotome II and Piezotome SOLO M+ with a piezotome‐adapted 3‐dimensional curved osteotomy surgical protocol
Number of subjects: 48
Study 29567435 — intervention group
Group type: COMPARATOR
Intervention: Traditional sliding genioplasty protocol
Number of subjects: 48
Study 28302271 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model for 30-day heart failure readmission
Number of subjects: 1475
Study 28302271 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1475
Study 25072666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental movement training (4 weeks, 4 × 30-minute sessions per week)
Number of subjects: 22
Study 25072666 — intervention group
Group type: COMPARATOR
Intervention: Generic multisport activity (control group)
Number of subjects: 22
Study 22943848 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System (EHCSS) series-K6 cigarette
Number of subjects: 0
Study 22943848 — intervention group
Group type: COMPARATOR
Intervention: Conventional lit-end cigarettes (CC)
Number of subjects: 0
Study 21099596 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based testing (swabs mailed to the participant's home)
Number of subjects: 558
Study 21099596 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based testing
Number of subjects: 558
Study 18498913 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose memantine 5 mg
Number of subjects: 40
Study 18498913 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose memantine 10 mg
Number of subjects: 40
Study 18498913 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose memantine 20 mg
Number of subjects: 40
Study 18498913 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose memantine 5 mg once daily for 14 days
Number of subjects: 40
Study 15941893 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.3 g . kg(‐1) . d(‐1))
Number of subjects: 102
Study 15941893 — intervention group
Group type: COMPARATOR
Intervention: Control supplementation (alanine)
Number of subjects: 102
Study 15941893 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 102
Study 15941893 — intervention group
Group type: COMPARATOR
Intervention: Control supplementation
Number of subjects: 102
Study 12906063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium milk fermented with B. longum strain BL1
Number of subjects: 32
Study 12906063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat drinking yogurt with B. longum strain BL1 (B-group)
Number of subjects: 32
Study 12906063 — intervention group
Group type: COMPARATOR
Intervention: Low-fat drinking yogurt with ordinary yogurt starters (P-group)
Number of subjects: 32
Study 12906063 — intervention group
Group type: COMPARATOR
Intervention: Milk fermented with mixed culture of ordinary yogurt starters (SL)
Number of subjects: 32
Study 12906063 — intervention group
Group type: COMPARATOR
Intervention: Acid milk (control)
Number of subjects: 32
Study 10562579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg orally twice a day for three months (n=10)
Number of subjects: 21
Study 10562579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 21
Study 8712447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine (50, 100, or 200 micrograms in D5NS)
Number of subjects: 58
Study 8712447 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (targeted to 50, 100, 200, or 400 ng/ml)
Number of subjects: 58
Study 8712447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of neostigmine and clonidine
Number of subjects: 58
Study 8712447 — intervention group
Group type: COMPARATOR
Intervention: D5NS (control group)
Number of subjects: 58
Study 1910342 — intervention group
Group type: EXPERIMENTAL
Intervention: FCH-free, NTG-containing spray (0.8 mg NTG)
Number of subjects: 15
Study 1910342 — intervention group
Group type: EXPERIMENTAL
Intervention: FCH- and NTG-containing spray (0.8 mg NTG)
Number of subjects: 15
Study 1910342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (FCH- and NTG-free spray, 2 puffs)
Number of subjects: 15
Study 1910342 — intervention group
Group type: EXPERIMENTAL
Intervention: NT/NR comparison
Number of subjects: 15
Study 6351988 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate
Number of subjects: 0
Study 6351988 — intervention group
Group type: COMPARATOR
Intervention: Stilbestrol
Number of subjects: 0
Study 6351988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 31876707 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 87
Study 31876707 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision cataract surgery (MICS)
Number of subjects: 87
Study 31876707 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery (CPS)
Number of subjects: 87
Study 26602701 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted exercise program
Number of subjects: 89
Study 26602701 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard exercise intervention
Number of subjects: 89
Study 26602701 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 89
Study 25238031 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-arch implant-fixed prostheses (G1)
Number of subjects: 29
Study 25238031 — intervention group
Group type: COMPARATOR
Intervention: Multiple implant splinting via acrylic resin denture bases (G2)
Number of subjects: 29
Study 25238031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 29
Study 24060817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mg I/mL
Number of subjects: 299
Study 22944060 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic rosuvastatin, 10 mg/day
Number of subjects: 83
Study 22944060 — intervention group
Group type: COMPARATOR
Intervention: CRESTOR, 10 mg/day
Number of subjects: 83
Study 20710084 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented low Dye (ALD) taping
Number of subjects: 13
Study 20710084 — intervention group
Group type: COMPARATOR
Intervention: Control tape
Number of subjects: 13
Study 20710084 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 13
Study 17411468 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive physical activity promotion programme
Number of subjects: 764
Study 17411468 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 764
Study 15868634 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made semirigid foot orthotics with shock absorbing posts (n = 15)
Number of subjects: 40
Study 15868634 — intervention group
Group type: COMPARATOR
Intervention: Off-the-shelf flat neoprene shoe inserts (n = 12)
Number of subjects: 40
Study 15868634 — intervention group
Group type: COMPARATOR
Intervention: Supportive athletic shoes with medial longitudinal arch support and shock absorbing soles (n = 13)
Number of subjects: 40
Study 11915378 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 12.5 mg
Number of subjects: 39
Study 11915378 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 25 mg
Number of subjects: 39
Study 11915378 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 39
Study 9793701 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan for treating migraine attacks
Number of subjects: 91
Study 7795344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention campaign to discourage prone sleeping
Number of subjects: 94
Study 1977980 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (metronidazole 20 mg/kg or 5 mg/kg daily, amoxycillin 25 mg/kg daily)
Number of subjects: 142
Study 1977980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 28976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg 15(S)15-methyl PGF2alpha methyl ester pessaries every 3 hours (maximum 4 doses)
Number of subjects: 28
Study 28976 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg 15(S)15-methyl PGF2alpha methyl ester pessaries every 3 hours (maximum 4 doses)
Number of subjects: 28
Study 28976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (1.0 mg and 1.5 mg)
Number of subjects: 28
Study 31788995 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-weekly carboplatin area under the curve 4 and pegylated liposomal doxorubicin (PLD) 30 mg/m², n=24
Number of subjects: 45
Study 31788995 — intervention group
Group type: COMPARATOR
Intervention: Observation, n=21
Number of subjects: 45
Study 31788995 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-weekly carboplatin area under curve 4 and pegylated liposomal doxorubicin (PLD) 30 mg/m², n=24
Number of subjects: 45
Study 30531572 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 56
Study 30531572 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 56
Study 28416342 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 1184
Study 26248312 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked schedule, extraneous focus condition
Number of subjects: 0
Study 26248312 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraneous attention
Number of subjects: 0
Study 23141780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 133
Study 23141780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 22043465 — intervention group
Group type: EXPERIMENTAL
Intervention: All-on-2 group
Number of subjects: 60
Study 22043465 — intervention group
Group type: COMPARATOR
Intervention: All-on-4 group
Number of subjects: 60
Study 22043465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 18592418 — intervention group
Group type: EXPERIMENTAL
Intervention: cNIRS monitoring
Number of subjects: 26
Study 18592418 — intervention group
Group type: COMPARATOR
Intervention: Serum from children undergoing evaluation for fever in the Emergency department (control)
Number of subjects: 26
Study 16363021 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bilateral breast reduction surgery
Number of subjects: 73
Study 16363021 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed surgery)
Number of subjects: 73
Study 12745614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal BDNF therapy
Number of subjects: 11
Study 12745614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10784225 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 93
Study 10784225 — intervention group
Group type: COMPARATOR
Intervention: Human soluble insulin (Humulin S)
Number of subjects: 93
Study 8818605 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Design Method (TDM)
Number of subjects: 0
Study 8818605 — intervention group
Group type: COMPARATOR
Intervention: Usual procedure
Number of subjects: 0
Study 1329477 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily lisinopril (5-20 mg)
Number of subjects: 31
Study 1329477 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily captopril (12.5-50 mg)
Number of subjects: 31
Study 4067891 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 305
Study 4067891 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercised)
Number of subjects: 305
Study 30567400 — intervention group
Group type: EXPERIMENTAL
Intervention: IQOSTM
Number of subjects: 30
Study 30567400 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Cigarette
Number of subjects: 30
Study 30567400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette
Number of subjects: 30
Study 28042578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy (inhalation of a blend of 1.0 mL of lemon and 0.5 mL of ginger essential oils)
Number of subjects: 71
Study 28042578 — intervention group
Group type: COMPARATOR
Intervention: Control (inhalation of distilled water as placebo)
Number of subjects: 71
Study 24296904 — intervention group
Group type: COMPARATOR
Intervention: Paraprofessional home visits
Number of subjects: 735
Study 24296904 — intervention group
Group type: COMPARATOR
Intervention: Nurse home visits
Number of subjects: 735
Study 22274951 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg intravenously on days 1 and 4 (schedule 1)
Number of subjects: 30
Study 22274951 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg intravenously on days 1, 3, and 5 (schedule 2)
Number of subjects: 30
Study 22274951 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing schedules of palonosetron
Number of subjects: 30
Study 20637970 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 50 mg
Number of subjects: 30
Study 20637970 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Number of subjects: 30
Study 20637970 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 30
Study 20637970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20637970 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil (all doses)
Number of subjects: 30
Study 19099009 — intervention group
Group type: EXPERIMENTAL
Intervention: GW406381 50 mg
Number of subjects: 1980
Study 19099009 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 1980
Study 19099009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1980
Study 19099009 — intervention group
Group type: EXPERIMENTAL
Intervention: GW406381 (1, 5, 10, 25, or 50 mg)
Number of subjects: 1980
Study 15914988 — intervention group
Group type: COMPARATOR
Intervention: 0 applications of plantibody
Number of subjects: 56
Study 15914988 — intervention group
Group type: COMPARATOR
Intervention: 2 applications of plantibody
Number of subjects: 56
Study 15914988 — intervention group
Group type: COMPARATOR
Intervention: 4 applications of plantibody
Number of subjects: 56
Study 15914988 — intervention group
Group type: COMPARATOR
Intervention: 6 applications of plantibody
Number of subjects: 56
Study 16400293 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 16400293 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer drugs (lamotrigine, levetiracetam, topiramate, zonisamide)
Number of subjects: 0
Study 16400293 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0
Study 16400293 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug combinations, vagal nerve stimulation, felbamate
Number of subjects: 0
Study 16400293 — intervention group
Group type: COMPARATOR
Intervention: Controlled clinical trials
Number of subjects: 0
Study 11746069 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication group (taught pain management and communication skills)
Number of subjects: 31
Study 11746069 — intervention group
Group type: COMPARATOR
Intervention: Control group (taught to use pain-intensity scales)
Number of subjects: 31
Study 9430449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) 2.0 microg/kg i.v.
Number of subjects: 7
Study 9430449 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) 0.17 U/kg i.m.
Number of subjects: 7
Study 9430449 — intervention group
Group type: EXPERIMENTAL
Intervention: Human corticotropin-releasing hormone (hCRH) 2.0 microg/kg i.v.
Number of subjects: 7
Study 9430449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) and AVP co-administration
Number of subjects: 7
Study 9430449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) and hCRH co-administration
Number of subjects: 7
Study 9430449 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH and AVP co-administration
Number of subjects: 7
Study 9430449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) alone
Number of subjects: 7
Study 8495455 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol LA 80 mg once daily
Number of subjects: 30
Study 8495455 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol LA 160 mg once daily
Number of subjects: 30
Study 8495455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3003166 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Pik oral irrigator
Number of subjects: 0
Study 31666688 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm
Number of subjects: 28
Study 31666688 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen (placebo)
Number of subjects: 28
Study 30354399 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 228
Study 30354399 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 228
Study 27240799 — intervention group
Group type: EXPERIMENTAL
Intervention: CHG-impregnated PICC line
Number of subjects: 167
Study 27240799 — intervention group
Group type: COMPARATOR
Intervention: non-CHG PICC line
Number of subjects: 167
Study 25218827 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 1800 mg
Number of subjects: 30
Study 25218827 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg + Donepezil 5 mg
Number of subjects: 30
Study 22931620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intestinal probiotics (Jinshuangqi Tablets, 2.0 g, 3 times daily)
Number of subjects: 60
Study 22931620 — intervention group
Group type: COMPARATOR
Intervention: Oral intestinal antimicrobial agents
Number of subjects: 60
Study 21095487 — intervention group
Group type: EXPERIMENTAL
Intervention: Norditropin FlexPro
Number of subjects: 56
Study 21095487 — intervention group
Group type: COMPARATOR
Intervention: easypod
Number of subjects: 56
Study 21095487 — intervention group
Group type: COMPARATOR
Intervention: Genotropin
Number of subjects: 56
Study 18388222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored information package including maps of pedestrian injuries for intervention politicians
Number of subjects: 615
Study 18388222 — intervention group
Group type: COMPARATOR
Intervention: General information pack for control politicians
Number of subjects: 615
Study 18388222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored information package
Number of subjects: 615
Study 17240625 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide treatment
Number of subjects: 0
Study 17240625 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 17240625 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with spontaneous platelet aggregation
Number of subjects: 0
Study 17240625 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ET
Number of subjects: 0
Study 12784123 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg THC
Number of subjects: 37
Study 12784123 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg THC
Number of subjects: 37
Study 12784123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 11111271 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle exchange program
Number of subjects: 0
Study 11111271 — intervention group
Group type: COMPARATOR
Intervention: Nonprogram areas
Number of subjects: 0
Study 8861742 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice a day)
Number of subjects: 65
Study 8861742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 1462746 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU alone (440 mg/m2 IV bolus 5/21 days)
Number of subjects: 41
Study 1462746 — intervention group
Group type: COMPARATOR
Intervention: Folinic acid (200 mg/m2 IV bolus 5/21 days) preceding 5‐FU (370 mg/m2 in short infusion 5/21 days)
Number of subjects: 41
Study 1462746 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post‐operative continuous portal infusion (5‐FU 500 mg/m2/day x 7 followed by a 2 hours infusion of mitomycin C 10 mg/m2)
Number of subjects: 41
Study 3912956 — intervention group
Group type: EXPERIMENTAL
Intervention: Veadent mouthwash
Number of subjects: 10
Study 3912956 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 10
Study 31412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of vegetables (41.28 g per portion at T0)
Number of subjects: 2286
Study 31412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of vegetables (36.67 g per portion at T1)
Number of subjects: 2286
Study 31412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of fruit (15.25 g per portion at T1)
Number of subjects: 2286
Study 31412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (39.26 g per 10 points at T0)
Number of subjects: 2286
Study 31412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Index (42.76 g per 10 points at T1)
Number of subjects: 2286
Study 31412688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (10.90 g per portion at T0)
Number of subjects: 2286